Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient and clinical characteristics (no. of patients (%))

From: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

  All (N=45) Pancreatic (N=19) Gastrointestinal intestinal and unknown origin (N=17) Others lung and paraganglioma (N=9)
Sex     
Male 32 (71.1) 15 (78.9) 9 (52.9) 8 (88.9)
Female 13 (28.9) 4 (21.1) 8 (47.1) 1 (11.1)
Age (yrs)     
Median (range) 52 (28-73)    
ECOG performance status     
0 36 (80.0) 13 (68.4) 17 (100) 6 (66.7)
1 6 (13.3) 3 (15.8) -- 3 (33.3)
2 3 (6.7) 3 (15.8)   
Ki67 index     
≤2 10 (25.6) 2 (11.8) 5 (33.3) 3 (42.8)
3-20 29 (74.4) 15 (88.2) 15 (66.6) 4 (57.2)
Missing 6 2 2 2
Octreoscan     
Positive 43 (95.6) 18 (94.7) 16 (94.1) 9 (100)
Negative 2 (4.4) 1 (5.3) 1 (5.9)  
Circulating chromogranin A     
Normal 8 3 (17.6) 4 (23.5) 1 (12.5)
Elevated 34 14 (82.4) 13 (76.5) 7 (87.5)
Missing 3 2 -- 1
Sites of metastatic disease     
Liver 41 (91.1) 18 (94.7) 16 (94.1) 7 (77.8)
Lymph nodes 17 (37.8) 6 (31.4) 8 (47.1) 3 (33.3)
Lung 5 (11.1) 0 (0) -- 4 (44.4)
Bone 2 (4.4) 2 (10.5) 1 (5.9) --
Syndrome 17 (37.8) 5 (26.3) 11 (64.7) 1 (11.1)
Diarrhea 10 (22.2) 3 (15.8) 6 (35.3) 1 (11.1)
Hot flashes 7 (15.6) -- 6 (35.3) 1 (11.1)
Rash 7 (15.6) -- 6 (35.3) 1 (11.1)
Hypoglycemia 1 (2.2) 1 (5.3) -- --
Cushing’s syndrome 1 (2.2) 1 (5.3) -- --
Previous treatments     
Surgery 34 (75.6) 13 (68.4) 14 (82.3) 7 (77.8)
Radiotherapy 2 (4.4) 2 (10.5) -- --
Radionuclide therapy with somatostatin analogues 23 (51.1) 10 (43.5) 8 (34.8) 5 (21.7)